Hypothesis

A senescence-targeted theranostic that couples an aptamer recognizing fibronectin variants with a lysosomally activated BCL‑XL inhibitor prodrug will selectively detect and eliminate resistant senescent cells, overcoming mitochondrial quality‑control–mediated resistance while sparing non‑senescent tissues.

Rationale

Aptamer‑based detection provides a live‑cell readout of senescent cells via surface fibronectin isoforms [1]. Senolytics such as ABT‑263 clear many senescent cells but leave subpopulations that survive through enhanced mitochondrial quality control [5]. Senescent cells display elevated lysosomal activity, including increased β‑galactosidase and cathepsin B expression, which can be harnessed to trigger prodrug release [6]. By linking the aptamer to a BCL‑XL inhibitor masked with a lysosomal‑cleavable peptide, the drug remains inert in circulation and is activated only after aptamer‑mediated internalization and lysosomal processing in senescent cells.

This approach integrates three layers of specificity: (1) aptamer binding to senescent surface markers, (2) lysosomal activation restricted to the senescent intracellular environment, and (3) BCL‑XL inhibition that triggers apoptosis in cells primed for death by mitochondrial stress. Together, it should reduce off‑target toxicity (e.g., thrombocytopenia) and eradicate resistant senescent subsets that current senolytics miss.

Experimental Design

1. In vitro validation – Treat human fibroblasts induced senescent by irradiation and proliferating controls with the aptamer‑prodrug conjugate. Measure aptamer binding (flow cytometry), lysosomal activation (fluorogenic cathepsin B substrate), and cell death (Annexin V/PI). Compare to free ABT‑263 and nanoparticle‑encapsulated ABT‑263.
2. In vivo imaging – Inject the aptamer‑radiolabel (e.g., ^64Cu) into young and aged mice; perform PET/CT to quantify senescent‑cell burden in liver, lung, and cartilage. Correlate signal with SA‑β‑gal staining.
3. Therapeutic efficacy – Aged mice receive intermittent dosing of the aptamer‑prodrug. Assess senescent‑cell clearance (aptamer signal reduction, p16^Ink4a^ qPCR), mitochondrial quality‑control markers (PINK1, Parkin), SASP cytokine plasma levels, and functional outcomes (grip strength, frailty index). Monitor platelet counts to detect thrombocytopenia.
4. Resistance test – Use a murine model where senescent cells overexpress Bcl‑2 or have enhanced mitophagy (e.g., Parkin overexpression). Determine whether the conjugate still clears these resistant populations.

Expected Outcomes

If the hypothesis holds, the aptamer‑prodrug will show: (a) high tumor‑to‑background ratio in PET imaging matching senescence markers; (b) significantly greater senescent‑cell reduction (>70%) compared with ABT‑263 alone, especially in lysosomal‑high subpopulations; (c) improved functional rescue without platelet decline; and (d) effective clearance of mitochondria‑resistant senescent cells. Failure to observe these outcomes would falsify the hypothesis, indicating that lysosomal activation does not confer sufficient specificity or that resistance mechanisms persist downstream of BCL‑XL inhibition.

Broader Impact

A theranostic that unites detection and lethal action could streamline preclinical aging studies, enable longitudinal monitoring of senolytic trials, and provide a path toward tissue‑specific senolysis that mitigates the cytokine power vacuum feared when SASP is globally suppressed [3].